The prevalence of TP53 mutations in cancer is well established, particularly in triple-negative breast cancer (TNBC), with certain mutation types consistently associated with poorer clinical outcomes across multiple cancers. This evidence concerns the gene TP53 and triple-negative breast carcinoma.